share_log

Summit Therapeutics Says Accepted Offers From Multiple Investors To Purchase Aggregate Of 10.35M Shares At $22.70 Per Share For Aggregate Gross Proceeds Of $235M

Benzinga ·  Sep 12 03:36

All of Summit's Section 16 officers participated in the capital raise. A total of $79 million was raised by insiders, including Robert W. Duggan, Dr. Maky Zanganeh, Manmeet S. Soni, and Bhaskar Anand, as well as Jeff Huber, a member of the Board of Directors, who invested via a controlled entity. The remaining $156 million was raised with multiple leading biopharma institutional investors.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment